Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (37)

« Back to Publications

The impact of pausing Bruton Tyrosine Kinase inhibitor (BTKi) therapy versus continued therapy on vaccination immune response in patients with chronic lymphocytic leukaemia: the IMPROVE RCT

Cook JA. et al, (2025), Efficacy and Mechanism Evaluation, 1 - 25

3-week pause versus continued Bruton tyrosine kinase inhibitor use during COVID-19 vaccination in individuals with chronic lymphocytic leukaemia (IMPROVE trial): a randomised, open-label, superiority trial.

Cook JA. et al, (2025), Lancet Haematol, 12, e294 - e303

Temporary 2-week suspension of methotrexate treatment to enhance COVID-19 vaccine response in people with immune-mediated inflammatory diseases: the VROOM RCT

Abhishek A. et al, (2025), Efficacy and Mechanism Evaluation, 1 - 42

Effects of temporarily suspending low-dose methotrexate treatment for 2 weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions: protocol for a multicentre randomised controlled trial and nested mechanistic substudy (Vaccine Response On/Off Methotrexate (VROOM) study)

Abhishek A. et al, (2025), Efficacy and Mechanism Evaluation, 12, 43 - 44

Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial

Abhishek A. et al, (2025), Efficacy and Mechanism Evaluation, 12, 47 - 48

Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial

Abhishek A. et al, (2025), Efficacy and Mechanism Evaluation, 12, 45 - 46

The protocol of a clinical effectiveness trial comparing standard step-up care, early combination DMARD therapy and early use of TNF inhibitors for the treatment of moderate to severe psoriatic arthritis: the 3-arm parallel group SPEED randomized controlled trial

Watson M. et al, (2024), Therapeutic Advances in Musculoskeletal Disease, 16

nti-TNF (adalimumab) injection for the treatment of pain-predominant early-stage frozen shoulder: the Anti-Freaze-Feasibility randomised controlled trial.

Hopewell S. et al, (2024), BMJ Open, 14

Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial.

Abhishek A. et al, (2024), Lancet Rheumatol, 6, e92 - e104

The protocol of a clinical effectiveness trial comparing standard step-up care, early combination DMARD therapy and early use of TNF inhibitors for the treatment of moderate to severe psoriatic arthritis: the 3-arm parallel group SPEED randomized controlled trial.

Watson M. et al, (2024), Ther Adv Musculoskelet Dis, 16

Protocol for a multicentre randomised controlled trial examining the effects of temporarily pausing Bruton tyrosine kinase inhibitor therapy to coincide with SARS-CoV-2 vaccination and its impact on immune responses in patients with chronic lymphocytic leukaemia.

Barber VS. et al, (2023), BMJ Open, 13

Optimising psoriatic arthritis therapy with immunological methods to increase standard evaluation: the protocol of an open-label multicentre, parallel-group, two-arm randomised controlled study evaluation precision medicine approach in the treatment of psoriatic arthritis.

Ooms A. et al, (2023), BMJ Open, 13

How should we best measure participant-reported ‘average hand pain’: comparison of two methods from a randomized placebo-controlled feasibility study of post-menopausal women with hand osteoarthritis

Williams JA. et al, (2023), Osteoarthritis and Cartilage, 31, s187 - s188

The Impact of Pausing Bruton Tyrosine Kinase Inhibitor Therapy and Responsiveness of Vaccination in Blood Cancer Patients: Primary Outcome Result for the Randomised Improve Trial

Patten P. et al, (2023), BLOOD, 142

Hormone replacement therapy (conjugated oestrogens plus bazedoxifene) for post-menopausal women with symptomatic hand osteoarthritis: primary report from the HOPE-e randomised, placebo-controlled, feasibility study.

Williams JAE. et al, (2022), Lancet Rheumatol, 4, e725 - e737

Load More